$HIMS Due Diligence — Hims Hers Health Inc
Buy · 7/10 — full report on Stockato.
- Price: $36.48
- Market cap: $8.0B
- Revenue (TTM): $2.4B
- Profit margin: -1%
VERDICT: BUY
SCORE: 7/10
CONFIDENCE: MEDIUM — mixed signals, insider and management strength offset valuation and options neutrality
COMPANY OVERVIEW
Hims & Hers operates a multi-specialty telehealth platform connecting consumers to licensed providers for personalized treatments, primarily in weight loss (GLP-1), hair loss, sexual health and dermatology. Headquartered in San Francisco, it reported $2.37B TTM revenue and is shifting toward a broader consumer-health platform with its own peptide manufacturing.
KEY FUNDAMENTALS
Revenue TTM $2.37B (+3.8% YoY quarterly), EBITDA $83M, gross margin 73%, operating margin -7.9%, EPS -0.09. Forward P/E 58.82, P/S 3.36, EV/Revenue 3.52 vs peers. Analyst consensus: 3 buy/strong-buy, 11 hold, 1 sell; target $28.42 vs current $36.48. Short interest 26.4% of shares, 3.27 days-to-cover. 52-week range $13.74–$70.43.
BULL CASE
- Quarterly revenue scaled from $316M (Q2 2024) to $608M run-rate with 8 straight beats/raises; management credibility 9/10.
- FDA PCAC meeting July 23–24 on 7 peptides for 503A bulk list could unlock post-2027 personalized compounding TAM >$20B (1% share = ~$200M).
- $400M JPMorgan receivables facility closed early July strengthens liquidity for GLP-1 scaling and international expansion.
- One open-market insider purchase of $1.17M in last 90 days; routine sells only.
BEAR CASE
- Forward P/E 58.82 and EV/EBITDA 222 price in aggressive growth while operating margin remains negative.
- Analyst target $28.42 implies 22% downside; 11 holds and 1 strong sell reflect valuation concerns.
- Short interest 26.4% and beta 2.60 amplify volatility around regulatory or margin outcomes.
- Non-binding FDA recommendation still requires 2027 rulemaking; commercialization timeline uncertain.
OPTIONS POSITIONING
MIXED_FLOW — 54% bullish premium ($469K calls vs $403K puts across 30 alerts, net +$67K). IV skew -3.25pp (calls richer). Largest trades: $137k BOUGHT CALL $36 2026-08-21; $81k BOUGHT CALL $44 2026-07-24 SWEEP; $80k SOLD CALL $35 2026-07-24; $78k SOLD PUT $33 2026-07-24; $39k SOLD CALL $40 2026-07-24. Flow is neutral/speculative and does not strongly confirm the fundamental catalyst.
X / SOCIAL CHATTER
FDA peptide meeting July 23–24 is viewed as binary long-term catalyst for post-2027 manufacturing/prescribing runway beyond Novo partnership (@TheStockerMan). $400M JPM facility seen as material liquidity buffer supporting $2.8–3.0B 2026 revenue target (@peterli34923561). Valuation premium could compress if GLP-1 margins face 2027 employer-coverage pressure.
MANAGEMENT CREDIBILITY
9/10 over 8 quarters; consistent beats and guidance raises while scaling revenue 2×. Only deduction for temporary noise around GLP-1 pivot, which was clearly communicated. No recurring excuses or goalpost moving.
KEY CATALYSTS
FDA Pharmacy Compounding Advisory Committee meeting July 23–24 on peptides; Q2 earnings (date TBD).
KEY RISKS
Regulatory delay or negative PCAC vote; sustained negative operating margins; short squeeze unwind if momentum stalls.
BOTTOM LINE
HIMS trades at a premium justified by execution and the July 23–24 binary catalyst, but the $28.42 analyst target and 26% short interest cap upside. Position for volatility around the FDA decision while monitoring margin trajectory.
How HIMS trades
53% below its 52-week high; worst drawdown in the past year 77%.
Moved 9.4% on average (absolute) across the last 8 earnings reports.
Behind SPY by 22.6 pts over 3 months.
Trades as a high-beta name: β 1.9 to QQQ, 7.0× SPY's volatility.
Realized volatility is 45% over 20 days, calmer than its 1-year 91%.
One-year beta: 2.67 to SPY, 1.86 to QQQ (data-vendor beta 2.43).
Correlation of daily returns: SPY 0.45 (60 days) / 0.38 (1 year); QQQ 0.52 (60 days) / 0.41 (1 year); IWM 0.53 (60 days) / 0.42 (1 year); XLV 0.08 (60 days) / 0.03 (1 year); 10y yield (daily change) -0.27 (60 days) / -0.14 (1 year).
Realized volatility: 45% (20 days), 84% (60 days), 91% (1 year).
Maximum drawdown over the past year -77%; -53% from the 52-week high.
HIMS options and volatility
25-delta puts trade 8.5 vol points below calls in the nearest monthly expiry.
ATM implied vol runs 96% at 1 day to 73% at 134 days (event kink at earnings).
Options price 1.52× the last 20 days' realized volatility — rich.
The first expiry after earnings (2026-11-13, 36 days out) prices ±20.4%, which also covers 36 days of ordinary movement; the average move on earnings day itself has been 9.4%.
Dealers are long gamma; call wall 30.0, put wall 28.0.
Options-implied expected moves: this week (2026-10-09): ±$1.19 (±4.03%); next monthly (2026-10-16): ±$2.41 (±8.14%); earnings expiry (2026-11-13): ±$6.02 (±20.38%).
Options data as of 2026-10-08 07:14 UTC.